## Verdict

verdict: PASS

```json
{
  "phase": "4.25",
  "verdict": "PASS",
  "iterations": 1,
  "entity_classes": {
    "citations": {
      "scanned": 9,
      "mismatch_count": 0,
      "mismatches": []
    },
    "institutions": {
      "scanned": 2,
      "mismatch_count": 0,
      "mismatches": []
    },
    "compound_identifiers": {
      "scanned": 4,
      "mismatch_count": 0,
      "mismatches": []
    },
    "regulatory_dates": {
      "scanned": 3,
      "mismatch_count": 0,
      "mismatches": []
    },
    "trial_registrations": {
      "scanned": 0,
      "mismatch_count": 0,
      "mismatches": []
    }
  },
  "halt_reasons": []
}
```

---

## Per-class prose tables

### 1. Citations (by PMID)

All 9 shared PMIDs checked for author/year/journal/volume/pages/DOI consistency across every section that cites them. Tag differences noted but ruled legitimate per-section-use (as specified).

| PMID | Sections citing | Author match | Year/Journal/Vol/Pages match | DOI match | Tag differences | Ruling |
|------|----------------|-------------|------------------------------|-----------|-----------------|--------|
| 11385580 (Ohtaki) | A, E | YES — Ohtaki T, Shintani Y, Honda S, et al. | YES — Nature 2001;411(6837):613-617 | YES — 10.1038/35079135 | A: `in_vitro`; E: `mechanism_review` | Legitimate section-local: A uses it for CHO-cell ligand-isolation context; E uses it as foundational discovery/mechanistic framing. NO mismatch. |
| 14573733 (Seminara) | A, E | YES — Seminara SB, Messager S, Chatzidaki EE, et al. | YES — NEJM 2003;349(17):1614-1627 | YES — 10.1056/NEJMoa035322 | Both `cohort` | CONSISTENT. |
| 19820030 (Jayasena 2009) | B, D | YES — Jayasena CN, Nijher GMK, Chaudhri OB, et al. | YES — JCEM 2009;94(11):4315-4323 | YES — 10.1210/jc.2009-0406 | Both `open_label`; D carries post-PMID study-design annotation | CONSISTENT. Post-PMID annotation in D is section-local, not a bib-metadata divergence. |
| 21632807 (George 2011) | A, B, D, E | YES — George JT, Veldhuis JD, Roseweir AK, et al. | YES — JCEM 2011;96(8):E1228-E1236 | YES — 10.1210/jc.2011-0089 | All `open_label`; D carries post-PMID PMC + study-design annotation | CONSISTENT. |
| 24517142 (Jayasena 2014) | A, B, D | YES — Jayasena CN, Abbara A, Veldhuis JD, et al. | YES — JCEM 2014;99(6):E953-E961 | YES — 10.1210/jc.2013-1569 | All `open_label`; D carries post-PMID PMC + study-design annotation | CONSISTENT. |
| 26192876 (Abbara 2015) | B, D | YES — Abbara A, Jayasena CN, Christopoulos G, et al. | YES — JCEM 2015;100(9):3322-3331 | YES — 10.1210/jc.2015-2332 | B: `open_label`; D: `rct` | Legitimate section-local: B explicitly labels the paper "open-label randomized (unblinded)" per its self-check; D emphasizes its Phase 2 randomized design. Both are textually defensible characterizations of a Phase 2 adaptive randomized but unblinded trial. NO bibliographic-metadata mismatch. |
| 28112678 (Comninos 2017) | C, E | YES — Comninos AN, Wall MB, Demetriou L, et al. | YES — J Clin Invest 2017;127(2):709-719 | YES — 10.1172/JCI89519 | C: `rct`; E: `open_label` | Legitimate section-local: C is the section specifically covering this RCT program and uses `rct`; E cites it in a COI/concentration context and uses `open_label`. Author/year/journal/DOI byte-identical. NO bibliographic-metadata mismatch. |
| 36287566 (Thurston 2022) | C, E | YES — Thurston L, Hunjan T, Ertl N, et al. | YES — JAMA Netw Open 2022;5(10):e2236131 | YES — 10.1001/jamanetworkopen.2022.36131 | Both `rct` | CONSISTENT. |
| 36735255 (Mills 2023) | C, E | YES — Mills EG, Ertl N, Wall MB, et al. | YES — JAMA Netw Open 2023;6(2):e2254313 | YES — 10.1001/jamanetworkopen.2022.54313 | Both `rct` | CONSISTENT. |

**Citations mismatch_count: 0**

---

### 2. Compound identifiers

| Identifier | Stated in | Value | Cross-section consistency |
|-----------|-----------|-------|--------------------------|
| KP-10 sequence | A (line 16) | YNWNSFGLRF-NH₂ (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂) | Not restated in B–E; no contradiction found. |
| KP-10 molecular weight | A (line 16) | 1302.5 Da | Not restated in B–E; no contradiction found. |
| KP-10 receptor | A, B (overview), C, D, E | KISS1R (GPR54) — consistent across all sections | CONSISTENT. |
| KP-10 vs KP-54 distinction | A (PK section), B (overview + B.4 note), D (D.1 + D.3), E (E.4) | KP-10 t½ ~4 min; KP-54 t½ ~27-28 min; same receptor; pharmacokinetically distinct | CONSISTENT — all sections frame KP-10 as the shorter isoform with the same receptor; no section conflates their clinical evidence. |

**Compound_identifiers mismatch_count: 0**

---

### 3. Institutions/concentration

| Fact | Sections | Value | Consistency |
|------|---------|-------|-------------|
| Imperial/Dhillo broad-field share | E (line 14) | ~45–55% of all primary human-dosing studies 2005–2024 | Stated only in E; C does not give a %. C says "all five RCTs were conducted exclusively at Imperial College London" for the sexual-brain sub-literature — consistent with E's ~100% HSDD sub-literature figure. NO contradiction. |
| Imperial/Dhillo HSDD sub-literature share | E (line 16) | ~100% — no independent replication | C (C.4) states same conclusion: "No independently led group has replicated the central claim." CONSISTENT. |
| Monash exclusion | E (line 18, line 80) | Monash excluded (animal models only; no human-dosing publications) | Not mentioned in C; C never counts Monash as a group. NO contradiction. |
| Four verified independent human-dosing groups | E | Edinburgh/MRC, Harvard/MGH, Mayo, Takeda/Ohtaki | C names Seminara/Crowley (Harvard/MGH) and Edinburgh/Anderson group in its independent-replication section — CONSISTENT with E's enumeration. |

**Institutions mismatch_count: 0**

---

### 4. Regulatory dates/facts

| Fact | Sections | Value | Consistency |
|------|---------|-------|-------------|
| FDA not-approved | A (implicit — no approved form noted), B (line 73: "No kisspeptin form is an approved drug anywhere"), D (line 56), E (line 32) | KP-10 not FDA-approved for any indication | CONSISTENT across B, D, E. |
| PCAC-October-2024-against-503A | D (line 58 — October 29, 2024 meeting, voted against), E (line 36 — "October 2024 meeting, voted against") | Both sections agree: PCAC Oct 2024 voted against 503A inclusion | CONSISTENT. D adds the specific date (Oct 29) and additional detail (Category 2 status post-April 2026 revision); E gives the same ruling without the additional timeline. No contradiction. |
| WADA S2.2.1 prohibition | D only (line 60) | Explicitly named S2.2.1 "Testosterone-Stimulating Peptides in Males"; in-competition and out-of-competition; male-specific | Not repeated in C or E; no contradiction found in any section. |

**Regulatory_dates mismatch_count: 0**

---

### 5. Trial registrations

No NCT numbers, ISRCTN identifiers, EudraCT numbers, or formal trial registration IDs appear in any of the five sections. No cross-section reconciliation possible or needed.

**Trial_registrations scanned: 0; mismatch_count: 0**
